These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 36748799)

  • 1. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
    Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
    Zhao M; Shao T; Shao H; Zhou C; Tang W
    BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
    Zheng B; Jiang H; Yang W; Li Y; Liang B; Zhu J; Chen N; Chen M; Zhang M
    Cancer Med; 2023 Aug; 12(15):15983-15997. PubMed ID: 37334877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis.
    Tao J; Zheng C; Zhang C; Zhou L; Liu Z; Zhou Y; Huang X; Lin L; Zhai L
    J Int Med Res; 2022 Nov; 50(11):3000605221132703. PubMed ID: 36380511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
    Luo X; Zhou Z; Zeng X; Peng L; Liu Q
    Front Public Health; 2022; 10():985834. PubMed ID: 36211665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer.
    Chuang CH; Chen HL; Chang HM; Tsai YC; Wu KL; Chen IH; Chen KC; Lee JY; Chang YC; Chen CL; Tu YK; Hung JY; Yang CJ; Chong IW
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.
    Jiang J; Zhao C; Zhang F; Liu Z; Zhou K; Ren X; Wan Y
    BMJ Open; 2022 Sep; 12(9):e060782. PubMed ID: 36123063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
    BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
    Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
    Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer.
    Zhao B; Han Y; Wang Y; Wang Y; Wang Y; Xing H; Dai C; Wang Y; Wang H; Ma W
    Pharmacol Res; 2021 Dec; 174():105931. PubMed ID: 34626769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
    Luo Y; Zhang Z; Guo X; Tang X; Li S; Gong G; Gao S; Zhang Y; Lin S
    Lung Cancer; 2023 Oct; 184():107319. PubMed ID: 37597303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis.
    Tao Y; Zhou Y; Tang L; Chen H; Feng Y; Shi Y
    Invest New Drugs; 2022 Aug; 40(4):831-840. PubMed ID: 35435628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
    Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
    Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
    Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
    J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
    Peng L; Lu D; Xia Y; Hong S; Selvaggi G; Stebbing J; Sun Y; Liang F
    Front Oncol; 2021; 11():754768. PubMed ID: 34820326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anaplastic lymphoma kinase inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
    Peng TR; Liao PF; Wu TW
    Thorac Cancer; 2023 Apr; 14(10):929-939. PubMed ID: 36908264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
    Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
    Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
    Fan J; Fong T; Xia Z; Zhang J; Luo P
    Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.